Use of electroconvulsive therapy in a patient with chorea neuroacanthocytosis and prominent delusions.

Rutherford M.

J ECT. 2012 Jun;28(2):e5-6. doi: 10.1097/YCT.0b013e31823c071d.

Behavioural state differentially engages septohippocampal cholinergic and GABAergic neurons in R6/1 Huntington's disease mice.

Ransome MI, Hannan AJ.

Neurobiol Learn Mem. 2012 Feb;97(2):261-70. doi: 10.1016/j.nlm.2012.01.004.

Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy.

Vidal RL, Figueroa A, Court FA, Thielen P, Molina C, Wirth C, Caballero B, Kiffin R, Segura-Aguilar J, Cuervo AM, Glimcher LH, Hetz C.

Hum Mol Genet. 2012 May 15;21(10):2245-62. doi: 10.1093/hmg/dds040.

Mutation in the CHAC gene in a family of autosomal dominant chorea-acanthocytosis.

Walker RH, Velayos-Baeza A, Bader B, Danek A, Saiki S.

Neurology. 2012 Jul 10;79(2):198-9; author reply 199. doi: 10.1212/01.wnl.0000416389.94466.01. No abstract available.

New Perspectives on the Neuropathology in Huntington's Disease in the Human Brain and its Relation to Symptom Variation.

Waldvogel HJ, Kim EH, Thu DC, Tippett LJ, Faull RL.

J Huntingtons Dis. 2012;1(2):143-53. doi: 10.3233/JHD-2012-120018. Review.

Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging.

Aggarwal M, Duan W, Hou Z, Rakesh N, Peng Q, Ross CA, Miller MI, Mori S, Zhang J.

Neuroimage. 2012 May 1;60(4):2086-95. doi: 10.1016/j.neuroimage.2012.01.141.

Perceived stress in prodromal Huntington disease.

Downing N, Smith MM, Beglinger LJ, Mills J, Duff K, Rowe KC, Epping E, Paulsen JS; PREDICT-HD Investigators of Huntington Study Group..

Psychol Health. 2012;27(2):196-209. doi: 10.1080/08870446.2010.529141.

Huntington's disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads database.

Kalathur RK, Hernández-Prieto MA, Futschik ME.

BMC Neurol. 2012 Jun 28;12:47. doi: 10.1186/1471-2377-12-47.

Deficits in spermatogenesis but not neurogenesis are alleviated by chronic testosterone therapy in R6/1 Huntington's disease mice.

Hannan AJ, Ransome MI.

J Neuroendocrinol. 2012 Feb;24(2):341-56. doi: 10.1111/j.1365-2826.2011.02238.x.

Metabolic and electrophysiological changes in the basal ganglia of transgenic Huntington's disease rats.

Vlamings R, Benazzouz A, Chetrit J, Janssen ML, Kozan R, Visser-Vandewalle V, Steinbusch HW, von Hörsten S, Temel Y.

Neurobiol Dis. 2012 Dec;48(3):488-94. doi: 10.1016/j.nbd.2012.07.006.

Induced pluripotent stem cell lines from Huntington's disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway.

Castiglioni V, Onorati M, Rochon C, Cattaneo E.

Neurobiol Dis. 2012 Apr;46(1):30-40. doi: 10.1016/j.nbd.2011.12.032.

An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease.

Fonteijn HM, Modat M, Clarkson MJ, Barnes J, Lehmann M, Hobbs NZ, Scahill RI, Tabrizi SJ, Ourselin S, Fox NC, Alexander DC.

Neuroimage. 2012 Apr 15;60(3):1880-9. doi: 10.1016/j.neuroimage.2012.01.062.

Is Huntington's disease associated with deficits in theory of mind?

Eddy CM, Sira Mahalingappa S, Rickards HE.

Acta Neurol Scand. 2012 Dec;126(6):376-83. doi: 10.1111/j.1600-0404.2012.01659.x.

Huntington's disease: objective assessment of posture--a link between motor and functional deficits.

Reilmann R, Rumpf S, Beckmann H, Koch R, Ringelstein EB, Lange HW.

Mov Disord. 2012 Apr;27(4):555-9. doi: 10.1002/mds.24908.

Neuroleptic Malignant Syndrome Induced by Olanzapine in a Patient with Huntington's Disease.

Moreno JL, Palau Fayos JM, Díaz de Santiago A, García de Yébenes J.

J Huntingtons Dis. 2012;1(1):31-2. doi: 10.3233/JHD-2012-120008. No abstract available.